2.507EUR-4.02%Mkt Cap: 475.44M EURP/E: —Last update: 2026-06-01
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese ence…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap475.44M EUR
Enterprise Value569.65M EUR
Revenue (TTM)156.33M EUR
Gross Profit67.52M EUR
Net Income (TTM)-115.19M EUR
Revenue/Share0.8970 EUR
Last Price2.507 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees674
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINCH0002088976
Valuation
P/E (Trailing)—
P/E (Forward)9.95
PEG-13.06
EV/EBITDA-6.96
EV/Revenue3.64
P/S3.17
P/B6.07
EPS (TTM)-0.80
EPS (Forward)0.26
52W Range
2.19010% of range5.415
52W High5.415 EUR
52W Low2.190 EUR
Profitability
Gross Margin38.66%
Oper. Margin-76.67%
EBITDA Margin-52.38%
Profit Margin-65.95%
ROE-108.50%
ROA-28.88%
Growth
Revenue Growth-37.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-52.89M EUR
CapEx (TTM)4.48M EUR
FCF Margin-19.83%
FCF Yield-6.52%
Net Debt104.24M EUR
Net Debt/EBITDA-1.27
Balance Sheet
Debt/Equity1.95
Current Ratio2.14
Quick Ratio1.23
Book Value/Sh0.4300 EUR
Cash/Share0.5910 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)5.233 EUR
Target Range2.100 EUR – 7.500 EUR
# Analysts6
Ownership
Shares Out.189.65M
Float147.38M
Insiders10.72%
Institutions23.31%
Technical
SMA 502.650 (-5.4%)
SMA 2003.777 (-33.6%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)1.12M
Avg Vol (10d)649.84K
Technical Indicators
RSI (14)50.5
MACD-0.0244
MACD Signal-0.0705
MACD Hist.+0.0461
BB Upper2.797 EUR
BB Middle2.513 EUR
BB Lower2.228 EUR
BB Width22.61%
ATR (14)0.1578 EUR
Vol Ratio (20d)0.94x